Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naproxcinod - Fera/Nicox

Next Previous
Drug Profile

Naproxcinod - Fera/Nicox

Alternative Names: AZD 3582; HCT 3012; Naproxen nitroxybutylester; Nitronaproxen; NO-naproxen

Latest Information Update: 04 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NicOx
  • Developer Fera Pharmaceuticals; NicOx
  • Class Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Sickle cell anaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Sickle cell anaemia
  • No development reported Osteoarthritis
  • Discontinued COVID 2019 infections; Duchenne muscular dystrophy

Most Recent Events

  • 29 Jul 2025 Preclinical development is ongoing Sickle cell anaemia in USA (Fera Pharmaceuticals pipeline, July 2025)
  • 28 May 2024 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA
  • 28 Apr 2022 Fera Pharmaceuticals plans for NDA submission for sickle cell disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top